Outcome of newly diagnosed children and adolescents with localized lymphoblastic lymphoma treated on Children's Oncology Group trial A5971: A report from the Children's Oncology Group
- 5 April 2012
- journal article
- clinical trial
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 59 (7) , 1229-1233
Abstract
Background: Localized lymphoblastic lymphoma (LL) is rare in pediatric patients. We report the 5‐year event‐free survival (EFS) and overall survival (OS) for children and adolescents with localized LL treated on a uniform regimen based on Children's Cancer Group (CCG) leukemia therapy (COG A5971).Procedure: From June 2000 to October 2005, the study enrolled 60 patients >12 months old with Murphy stages I or II LL. Central review confirmed 56 eligible patients. Treatment consisted of 24 months of CCG BFM without day 28 intrathecal methotrexate in maintenance therapy or prophylactic cranial radiation.Results: Most patients had pre‐B immunophenotype (75%). At a median follow‐up of 5.9 years (range 1.4–9.3 years), the 5‐year EFS was 90% [95% confidence interval (CI), 78–96%] and the 5‐year OS was 96% (95% CI, 84–99%). Stage (I vs. II), immunophenotype, elevated LDH > institutional normal, or primary site did not impact outcome. Five relapses occurred—none in the CNS and none in patients with pre‐T lymphoblastic disease. Patients tolerated treatment well with no toxic deaths.Conclusion: Outcomes of pediatric patients with localized LL treated with 2 years of intensive acute lymphoblastic leukemia (ALL)‐type therapy was excellent and is similar to the outcome for standard risk ALL treated less intensively. CNS prophylaxis was adequate with limited intrathecal methotrexate and no radiation. Future studies should identify biologic prognostic factors or biomarkers for pediatric patients with LL, explore less intensive treatment for patients with localized disease, and explore novel immunophenotype directed therapies. Pediatr Blood Cancer 2012; 59: 1229–1233.Keywords
This publication has 33 references indexed in Scilit:
- Long‐term results of AIEOP LNH‐92 protocol for the treatment of pediatric lymphoblastic lymphoma: A report of the Italian Association of pediatric hematology and oncologyPediatric Blood & Cancer, 2009
- Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy: Long term results of the EORTC CLG 58881 trialEuropean Journal of Cancer, 2008
- The impact of age and gender on biology, clinical features and treatment outcome of non‐Hodgkin lymphoma in childhood and adolescenceBritish Journal of Haematology, 2005
- Lymphoblastic lymphoma of childhood and the LSA2‐L2 protocolCancer, 2003
- Precursor B-cell lymphoblastic lymphoma in childhood and adolescence: Clinical features, treatment, and results in trials NHL-BFM 86 and 90Medical and Pediatric Oncology, 2000
- Comparison of treatment regimens for pediatric lymphoblastic non-Hodgkin's lymphoma: a Childrens Cancer Group study.Journal of Clinical Oncology, 1995
- Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster Group.Journal of Clinical Oncology, 1995
- Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: a report of CCG-551 from the Childrens Cancer Group.Journal of Clinical Oncology, 1993
- Results of the LMT81 protocol, a modified LSA2L2 protocol with high dose methotrexate, on 84 children with non‐B‐cell (lymphoblastic) lymphomaMedical and Pediatric Oncology, 1992
- Non-Hodgkin's lymphoma in children. A comparative study of two modalities of therapyCancer, 1976